Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)CARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the Company will host a conference call and webcast on Tuesday, September 15, 2026 at 8:30am ET to discuss topline results from its Phase 2 ADDRESS-LC trial (NCT06847191